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BACKGROUND
• Cardiogenic shock (CS) occurs when perfusion needs
are not being met due persistent hypotension and a
low cardiac output from the left ventricle.1
• Veno-arterial extracorporeal membrane oxygenation
(VA-ECMO) provides full cardiopulmonary support
temporarily to CS patients awaiting further
treatment.2
• Due to afterload caused by VA-ECMO, it can be
beneficial to use unloading strategies , such as an
Impella heart device to provide further support to
the left ventricle.3

OUTCOMES

Figure 1: Outcomes were
determined at the time of
discharge for cardiogenic
shock patients receiving
VA-ECMO or VAECMO/Impella.

RESULTS
• VA-ECMO only group had a 39.4%  survived to
discharge
• VA-ECMO & Impella group had a 40%  survival to
discharge
• 73%  of those who had renal failure pre surgery
died in both groups
• An alternative heart device, IABP was used on 7  
patients with an increased survival of 57.1%   to
discharge
• Previous VA-ECMO study confirms about 43%  
survival.

CONCLUSION

OBJECTIVE

• Similar outcomes between the two groups suggest
no clear advantage of unloading the left ventricle
with Impella.
• A higher survival rate with IABP might suggest
future studies regarding its’ outcome.
• Renal failure pre-surgery can be an indicator for an
increased mortality risk, since VA-ECMO alone has
shown the same mortality.
• Future studies: matched patients and larger cohort.

• Since the literature remains undecided regarding the
benefit of unloading the left heart, this study investigates
the outcomes of VA-ECMO patients with and without the
Impella heart device at the Lehigh Valley Health Network.

METHODS
• Retrospective chart review of patients receiving VAECMO at Lehigh Valley Hospital from 2013-2018
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• 25 patients on VA-ECMO & Impella
• 104 patients on VA-ECMO only
• Analysis of patient demographics, outcomes, and
comorbidities

Figure 2: Secondary outcomes and comorbidities of patients on VAECMO and VA-ECMO/Impella.
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